Health ❯ Public Health ❯ Obesity

Weight Management

Medications GLP-1 Drugs Pharmaceuticals Weight-loss Drugs Weight Loss Drugs Medication Use Anti-Obesity Medications GLP-1 Medications Impact on Industries Prehabilitation Mindfulness Weight-Loss Injections NHS Services Clinical Implications NHS Policies Prescription Medications Treatment Strategies Weight Loss Treatments Cravings Personalized Medicine Drug Accessibility Semaglutide BMI Measurement Medication Access Mounjaro Weight Loss Injections Dietary Drugs Pharmaceutical Interventions Healthcare Services Medications for Obesity

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Phase 3 trials are set to begin this quarter following 48-week topline data showing large placebo-adjusted weight loss.

Trump Cites 'Very Fat' Friend's Ozempic Story to Decry Price Gap

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

U.S. Obesity Rate Drops to 37% as GLP-1 Use Surges, Gallup Finds